Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck’s Saphris Gets FDA Letter After Taking Informant To Lunch

This article was originally published in The Pink Sheet Daily

Executive Summary

A complaint to the “Bad Ad” program that a speaker had promoted an unapproved use for Merck’s atypical antipsychotic Saphris leads FDA’s Office of Prescription Drug Promotion to issue a “notice of violation” letter.

You may also be interested in...



"Bad Ad" Program Set To Expand After Opening Spigot Of Complaints In Year One

In its first year of operation, FDA's "Bad Ad" program succeeded in more than tripling the number of complaints the agency receives about deceptive drug advertising, and now the agency is assessing how best to expand upon the success of the initiative.

Forest Admits To Knowingly Obstructing FDA Inspection In Guilty Pleas On Levothroid, Celexa Marketing

Forest Pharmaceuticals reached a $313 million settlement with the Department of Justice to resolve criminal charges of obstructing an FDA inspection and distributing a misbranded drug and civil False Claims Act allegations.

Ranbaxy’s Atorvastatin Recall: Will Glass Shards Nick FDA’s Reputation?

Less than a year after signing a consent decree to resolve compliance problems, the company is forced to stop manufacturing its generic version of the best-selling cholesterol drug. For FDA, the issue poses a public relations challenge since it touches on several areas where the agency has recently been criticized – generic drug quality, manufacturing oversight and drug shortages.

Topics

Related Companies

UsernamePublicRestriction

Register

ID005817

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel